Randomized, blind, parallel, and positive-controlled Phase I clinical trials of subcutaneous fat layer injection treatment in people with excess subcutaneous fat accumulation in Chinese jaws

开始日期2025-07-01

申办/合作机构

北京协和医院

[+1]

NCT06300502

/ Enrolling by invitation临床1期IIT

Assessing the Efficacy of Repeat, Monthly Treatments of Cutaneous Neurofibromas (cNFs)

The goal of this clinical trial is to evaluate the tolerability and effectiveness of multiple treatments of an FDA-approved drug in those with Neurofibromatosis Type 1 (NF1) Cutaneous Neurofibromas (cNFs). The main questions it aims to answer are:
Will performing:
* Up to 6 months treatment sessions
* A minimum of 30 days apart
* With up to 50 injections of deoxycholate into a maximum of 50 cNFs in a single region of the body (for a maximum total dose of 10 mL per monthly treatment session) result in tolerable local skin reactions and reduction in both individual cNF size by >50% as well as improved cNF appearance in the treated field?
Researchers will compare treated tumors and control tumors to see if the treatment is effective.
Participants will:
* Receive up to 6 monthly treatments with Kybella (deoxycholate). Treatment for a given tumor will be stopped when the tumor is assessed as clear clinically.
* Complete surveys asking about pain during and after treatments.
* Complete surveys asking about satisfaction with the treatments.
* Undergo 2D photography and 3D imaging of treatment areas.
* Optionally, receive biopsies of up to 6 treated lesions to investigate characteristics of tumors that respond well to treatment as well as non-respondent tumors.

开始日期2025-04-08

申办/合作机构

The General Hospital Corp.

[+1]

100 项与脱氧胆酸相关的临床结果

登录后查看更多信息

100 项与脱氧胆酸相关的转化医学

登录后查看更多信息

100 项与脱氧胆酸相关的专利（医药）

登录后查看更多信息

7,961

项与脱氧胆酸相关的文献（医药）

2026-12-01·JOURNAL OF MEMBRANE BIOLOGY

Peptide-Assisted Membrane Permeabilization: Effects of Waveform Polarity, Inter-Monopulse Interval, and Surface Charge in Red Blood Cells and Planar Lipid Bilayers

Article

作者: Lemeshko, Victor V ; Alvarez-Bustamante, José Alexander ; Ortiz-Mejía, Diego

Permeabilization of biomembranes by polycationic peptides is known to depend on the membrane potential, although the exact mechanism of this process is not yet completely defined, to be effectively controlled. We quantified peptide-assisted permeabilization of red blood cells (RBCs) using a custom system that delivered microsecond bipulses configured as bimonopolar (BMP; same polarity) or bipolar (BP; opposite polarity), varying the inter-monopulse interval ([Formula: see text]). In RBC suspensions, bulk light transmittance at 650 nm showed that BMP yielded higher permeabilization effect than BP at short [Formula: see text], whereas lengthening [Formula: see text] mitigated bipolar cancellation and increased BP responses. Membrane surface charge modulation by moderate concentrations of deoxycholate and spermine increased and decreased, respectively, membrane permeabilization effects of polycationic peptides. Complementary measurements in planar lipid bilayers (BLMs) under an applied command voltage ([Formula: see text]) with polarity alternation showed remarkable conduction at negative bias, essentially decreased in the presence of 1 mM Mg²⁺. Infrared thermometry over RBC suspension revealed modest heating (≈ 2.5-6 °C), equal for BMP and BP applications, indicating an electrical rather than thermal origin for waveform effects. Finally, the designed electroporation protocols allow controlled short-time permeabilization of cell membrane that might be useful for biotechnological applications and therapeutic delivery.

2026-06-01·International Journal of Pharmaceutics-X

Hyaluronic acid microneedle patch for transdermal delivery of naringin-loaded PEGylated terpesomes in a rat model of rheumatoid arthritis: Modulation TGF-β1, oxidative stress, and inflammation

Article

作者: Ewedah, Tassneim M ; Morsy, Suzan Awad AbdelGhany ; Fouad, Marwa A ; Shoela, Mai S ; Albar, Halah Tariq ; Hassan, Fatma E ; Elsayed, Mahitab ; Elmoneim, Hanan Mohamed Abd ; Hamdan, Ahmed Mohsen Elsaid ; Elsharkawy, Amal M ; Allam, Shady ; Abdelgawad, Wedian Younis ; Elhabal, Sammar Fathy ; Saad-Eldin, Rana

Rheumatoid arthritis (RA) is a chronic autoimmune inflammatory disease that causes progressive joint damage and systemic effects. Naringin (NRG), a citrus-derived flavonoid with potent anti-inflammatory and antioxidant activities, is hindered by poor solubility and low bioavailability in clinical applications. NRG was encapsulated into PEGylated terpesomes (TPs) prepared by thin-film hydration using phosphatidylcholine, terpenes, and sodium deoxycholate, then integrated into hyaluronic acid-based microneedles (NRG-TPs/HA-MNs) to create a dual-mechanism transdermal delivery system. Optimized NRG-loaded terpesomes possessed a nanoscale particle size (218 ± 0.67 nm), a narrow polydispersity index (PDI: 0.32 ± 0.05), a high entrapment efficiency (79 ± 0.23%), and strong colloidal stability (Zeta potential: -36.37 ± 0.87). HA-MN patches exhibited remarkable mechanical strength, high drug loading (>93%), and successful skin penetration. NRG release was sustained for over 48 h, and transdermal permeation was significantly improved compared to free NRG in both in vitro and ex vivo studies. In a Complete Freund's Adjuvant-induced RA rat model, NRG-TPs/HA-MNs significantly reduced paw edema and joint swelling, preserved joint architecture on X-ray imaging, and ELISA analysis indicated significant decreases in inflammatory mediators TNF-α, IL-1β, IL-6, NF-κB, and MMP-3. qPCR analysis of the genes MYD88, TXNIP, and BCL-2 showed the therapeutic potential of this system, accompanied by decreased levels of the oxidative stress marker malondialdehyde (MDA), suggesting modulation of the mTOR signaling pathway. Elevated transforming growth factor-β expression and histopathology confirmed cartilage protection and tissue repair. NRG-terpesomal incorporated into the HA-microneedle system provides a minimally invasive therapeutic platform for the sustained release of drugs with improved permeation in the treatment of Rheumatoid arthritis.

2026-05-01·MOLECULAR AND CELLULAR ENDOCRINOLOGY

Plasma proteome mendelian randomization and network pharmacology reveal therapeutic targets for thyroid disorders

Article

作者: Cai, Yi ; Yang, Xing ; Jie, Jie ; Wang, Chao

INTRODUCTION:

Thyroid disorders, including hypothyroidism, hyperthyroidism, and thyroid cancer, impose a substantial global health burden. Existing treatments face limitations due to adverse effects and incomplete efficacy, highlighting the need for innovative therapeutic strategies informed by genetic and molecular insights.

METHODS:

We integrated Mendelian randomization (MR) with network pharmacology to systematically prioritize druggable targets. Genetic correlations between different thyroid disorders were evaluated using linkage disequilibrium score regression analysis. Plasma protein quantitative trait loci from 4907 plasma proteins were leveraged as instrumental variables in MR analyses across two independent cohorts. Bayesian colocalization validated shared causal variants. Network pharmacology methods encompassed constructing protein-protein interaction networks, conducting functional enrichment analyses, and identifying potential therapeutic compounds via the DSigDB database. Docking and dynamics simulations assessed binding and stability, while PheWAS assessed off-target effects.

RESULTS:

The LDSC analysis identified notable genetic correlations of hypothyroidism with hyperthyroidism (Rg = 0.167, P = 0.017), as well as hyperthyroidism with thyroid cancer (Rg = 0.286, P = 0.033). MR and colocalization identified seven causal proteins: IL2RB, CDH1, FGF19 (hypothyroidism); PSAPL1 (hyperthyroidism); DCP1B, SPRN, RPS6KA6 (thyroid cancer). Drug prediction prioritized compounds such as BI-2536 (binding energy: -9.5 kcal/mol with RPS6KA6) and deoxycholic acid. PheWAS confirmed minimal pleiotropic risks.

CONCLUSIONS:

By synergizing genetic epidemiology with network pharmacology, this study delineates shared genetic architecture among thyroid disorders and nominates seven high-confidence targets with therapeutic potential. The integrative framework advances precision medicine by bridging causal plasma protein identification, mechanistic pathway mapping, and drug repurposing, offering a blueprint for multi-omics-driven drug discovery in endocrine pathologies.

项与脱氧胆酸相关的新闻（医药）

2026-04-17

·罗密欧与猪guo夜

地表最强溶脂针——Belkyra（倍克脂）改善口角囊袋和双下巴

说到双下巴，很多人不胖，但脸就是显圆、显钝、显老。运动减不掉，按摩没用，又不想做手术。于是出现了一款被全球医美公认为 “双下巴专用溶脂黑科技”—— Belkyra（也叫Kybella）。今天我们不吹不黑，直接基于国际权威期刊文献PMC7099849的研究结论，把它讲透。一、Belkyra 到底是什么？ 🔹 品牌与产地：美国原厂，医美巨头出品 • 研发主体：最初由美国生物制药公司 Kythera Biopharmaceuticals 研发 • 所属集团：2015年被全球医美巨头 Allergan（爱力根，现属AbbVie）收购 • 原厂产地：美国制造，为处方级医疗注射剂 🔹 上市历程：全球首款，权威认证 • 2015年4月29日：获美国FDA批准，成为全球首个用于双下巴的注射溶脂药（商品名Kybella） • 2017年：获欧盟EMA、台湾卫福部核准上市（商品名Belkyra） • 全球覆盖：已在100+国家获批，临床数据超20项、受试者超2600人、5年长期追踪二、Belkyra 核心成分是什么？核心成分：合成脱氧胆酸（DCA） 🔹 它不是外来物，是人体生理物质 • 人体内肝脏合成、胆囊储存的天然胆汁酸之一 • 生理功能：乳化、分解、吸收食物脂肪，参与肠道脂肪代谢 • Belkyra为100%生物等效的合成版本，与人体自身DCA结构完全一致 🔹 为什么它能精准溶脂？原理深度拆解（PMC文献实证） 1. 物理性破坏脂肪细胞膜（核心机制） DCA是天然生物表面活性剂，分子一端亲水、一端亲脂 • 精准插入脂肪细胞膜磷脂双分子层，破坏膜完整性、形成穿孔 • 脂肪细胞结构崩解、内容物泄漏，细胞不可逆坏死 2. 靶向性：只溶脂肪，不伤其他组织 • 对蛋白质丰富的组织（皮肤、肌肉、神经、血管）无损伤 • 仅作用于皮下脂肪层，安全性来自“组织选择性” 3.效果持久：脂肪细胞不会再生 • 溶解的是脂肪细胞数量，而非缩小体积 • 临床证实：效果长期稳定，可达10年+ • 多数人2–4次疗程达到理想效果，满意度达93% 患者与方法研究设计与患者选择这项前瞻性干预性研究在纽约州卢舒尔格里（Luxurgery）单一地点进行，遵循赫尔辛基宣言和国际协调会议三方良好临床实践指南。研究期为1年（2016年1月1日至12月31日）。每位患者均获得了书面和口头知情同意。所有患者均为下颌线可捏脂肪的成年人。颌骨中度至重度皮肤松弛是ATX-101（倍克脂）治疗的相对禁忌症。下颌皮肤极度松弛的患者被排除。治疗方法患者符合接受ATX-101治疗的条件，以减少下颌脂肪和额下脂肪。大多数下颌脂肪治疗与下颌脂肪治疗在同一次治疗中进行，尽管部分患者在完成下颌脂肪治疗课程后继续进行下颌治疗。建议用于ATX-101治疗心下脂肪的1.0厘米注射格网，每次注射0.2毫升（面积调整剂量：2 mg/cm2），除非表面积较小，否则在颌部使用。在表面积有限的情况下，注射0.1毫升，间隔为0.50至0.75厘米。每次注射深度为6至10毫米，使用0.5英寸、32号针头。注射部位位于下颌下骨边缘上方、前切迹前方、口腔连合延伸至前颌沟的尾侧，以及中线唇脑沟延伸至耳叶所形成线下方的解剖区（见图1）。[参见视频（在线），展示了将ATX-101注射到患者下颌脂肪垫的标记。] 注射过程中，脂肪和皮肤被夹紧并拉离下方的肌肉和神经血管结构。该技术通过呈现目标区域并优化注射角度，实现垂直注射进入颌骨脂肪。下颌神经的末端树状化通常发生在下颌骨，但深入至皮下脂肪。捏合并拉回皮肤和脂肪可以降低暂时性下颌神经瘫痪的可能性。减少不良事件的舒适措施包括局部麻醉（治疗前10分钟使用利多卡因加上肾上腺素）、注射后冰敷（治疗后48小时）和注射后口服镇痛（对乙酰氨基酚）。治疗结果本研究中，66名患者接受ATX-101治疗以减少下颌脂肪（见表1）。平均年龄为46.4岁（范围为23至68岁），女性占58%。一半的患者之前接受过美容手术。每位患者减少下颌脂肪的ATX-101治疗平均次数为1.8次。平均ATX-101注射量为每次治疗每下颌0.8毫升，平均注射间隔为8.6周。15名患者接受0.1毫升注射，其余51名患者在颌部注射0.2毫升。所有患者均同时或分开接受下颌脂肪和颅下脂肪治疗。 98%的患者（65/66）实现了颌骨外观的改善一名59岁女性患者接受了两次ATX-101治疗，分别减少下颌脂肪（每次下颌脂肪1.0毫升;总体积：4毫升）和额下脂肪（分别为8和6毫升;总体积：14毫升）。这里拍摄的是她在第一次治疗前（上图）和最后一次治疗后6个月（下图）。一名62岁男性患者在三个月内接受了两次ATX-101治疗，以减少下颌脂肪。两侧颌骨均等且双侧分别施用1.2毫升和0.8毫升。这是他在第一次治疗前（上图）和第二次也是最后一次治疗后9个月（下图）的画面。一名47岁女性患者在9个月内接受了三次ATX-101治疗（分别为5毫升、5毫升、2毫升），以减少口角囊袋和下颌脂肪。颌骨均等且双侧均用，分别为1.2毫升、0.8毫升和0.6毫升。这里拍摄她在第一次治疗前（上图）和第三次也是最后一次治疗后6个月（下图）。常见注射部位不良事件包括水肿、麻木、压痛和瘀伤，均持续4至29天。三名患者经历注射部位下颌神经麻痹，平均26天内缓解（范围为14至40天）。3名患者经历注射部位脱发，均期为95天（范围64至126天）内缓解。 so为什么说belkyra是地表最强溶脂？ 🔹 全球唯一：FDA/EMA双认证，双下巴专用 • 唯一获FDA批准用于颏下脂肪的注射溶脂产品 • 靶点最精准：专门针对双下巴，不扩散、不影响面部轮廓 🔹 效果持久：脂肪细胞不会再生 • 溶解的是脂肪细胞数量，而非缩小体积 • 临床证实：效果长期稳定，可达10年+ • 多数人2–4次疗程达到理想效果，满意度达93% 🔹 非手术、不留疤、恢复期短 • 注射治疗，无需开刀、无需住院、无疤痕一句话总结：不是强行“烧脂”，而是让身体用天然机制，把脂肪细胞彻底溶解并代谢掉。 #溶脂针#口角囊袋#碎脂针了解更多医美前沿资讯，及产品信息快快长按二维码关注我们吧 ☟☟☟ 长按添加客服

2026-04-14

·adhexpharma.com

Buccal delivery of peptides: a new publication from the BUCCAL-PEP consortium

by Nicolas Rollet on Apr 14, 2026 8:43:48 AM A new scientific article has been published in Carbohydrate Polymers as part of the European BUCCAL-PEP consortium, of which AdhexPharma is a partner. This study, led by Sandeep Karki from University College Dublin in collaboration with several consortium partners, including AdhexPharma and Dr Nicolas Rollet, presents the development of a pullulan-based bilayer film for the buccal delivery of a GLP-1 peptide analogue. This approach uses epithelial permeation enhancers to improve peptide absorption. Read the article: https://doi.org/10.1016/j.carbpol.2026.125064 Figure 1 : Design of an oral bilayer buccal film (OBF) [1] Therapeutic peptides offer significant clinical potential, but their administration is still often limited by the need for injection or by the challenges associated with conventional oral dosage forms. The buccal route represents a promising alternative, as it can partially bypass gastrointestinal degradation and first-pass hepatic metabolism. In this study, researchers developed a bilayer buccal film designed to improve the local delivery and permeation of a GLP-1 analogue across the buccal mucosa. The buccal route can help overcome gastrointestinal degradation and first-pass metabolism, offering several advantages: Painless, non-invasive administration No complex fasting or water intake requirements (unlike oral semaglutide) Rapid mucosal absorption Reduced dosing variability However, peptides generally show very low permeability across the buccal epithelium, which makes the development of new formulation technologies essential. [4] [5] The innovation behind the bilayer film [6], [7] The researchers developed a bilayer film made of two complementary layers: 1. Mucoadhesive Layer (facing the cheek mucosa) Polymers tested: Pullulan, HPMC, PVA Selected combination: Pullulan + Sodium Carboxymethyl cellulose (NaCMC) GLP-1 RA peptide Sodium glycodeoxycholate (GDC), a bile salt permeation enhancer GLP-1 RA peptide Sodium glycodeoxycholate (GDC), a bile salt permeation enhancer 2. Backing Layer (saliva repellent) Made with Eudragit® RLPO Directs drug release toward the epithelium, preventing loss via saliva Encouraging ex vivo results [8] Pullulan-based film outperformed all others Best mucoadhesion, mechanical strength, and surface morphology Fastest disintegration of the mucoadhesive layer Highest and most consistent drug release profile Best mucoadhesion, mechanical strength, and surface morphology Fastest disintegration of the mucoadhesive layer Highest and most consistent drug release profile Optimal peptide–enhancer ratio identified Using ex vivo porcine tissue: A 1:2 ratio (GLP-1 RA:GDC) produced the highest peptide permeation (~6% at 3 h). A 1:2 ratio (GLP-1 RA:GDC) produced the highest peptide permeation (~6% at 3 h). Effective ex vivo permeation from films Single-layer films (no backing): ~4.5% flux at 3 h Bi-layer films (clinical candidate): ~2% flux at 3 h Backing layer reduces immediate release but enhances controlled, unidirectional absorption. Single-layer films (no backing): ~4.5% flux at 3 h Bi-layer films (clinical candidate): ~2% flux at 3 h Backing layer reduces immediate release but enhances controlled, unidirectional absorption. Minimal tissue damage The bi-layer architecture moderated GDC exposure Histology showed preserved epithelial integrity Confocal imaging confirmed controlled penetration The bi-layer architecture moderated GDC exposure Histology showed preserved epithelial integrity Confocal imaging confirmed controlled penetration Chemical and structural stability Both peptide and GDC remained stable for at least 1 month at 4°C Circular dichroism confirmed preserved αhelical peptide structure Both peptide and GDC remained stable for at least 1 month at 4°C Circular dichroism confirmed preserved αhelical peptide structure An important milestone for non-invasive peptide therapies [9], [10] This study represents the first demonstration of co-formulating a GLP-1 analogue and sodium glycodeoxycholate in a pullulan-based bilayer film capable of improving buccal permeation. This technology could help advance therapeutic approaches in: Type 2 diabetes Obesity Other peptide-treated conditions It may also help address adherence challenges associated with injectable therapies and the strict administration requirements of oral semaglutide. Conclusion This pullulan-based bilayer film platform represents a promising and patient-friendly approach for the controlled buccal delivery of non-injectable therapeutic peptides. Thanks to its robust mechanical properties, excellent mucoadhesion, and significant improvement in peptide permeation, it could pave the way for a new generation of peptide therapies. [1] S. Karki et al., « A pullulan-based bilayer film for buccal delivery of a GLP-1 peptide analogue », Carbohydr. Polym., vol. 380, p. 125064, mai 2026, doi: 10.1016/j.carbpol.2026.125064. [2] B. J. Teubl, M. Absenger, E. Fröhlich, G. Leitinger, A. Zimmer, et E. Roblegg, « The oral cavity as a biological barrier system: Design of an advanced buccal in vitro permeability model », Eur. J. Pharm. Biopharm., vol. 84, no 2, p. 386‑393, juin 2013, doi: 10.1016/j.ejpb.2012.10.021. [3] B. J. Teubl, M. Absenger, E. Fröhlich, G. Leitinger, A. Zimmer, et E. Roblegg, « The oral cavity as a biological barrier system: Design of an advanced buccal in vitro permeability model », Eur. J. Pharm. Biopharm., vol. 84, no 2, p. 386‑393, juin 2013, doi: 10.1016/j.ejpb.2012.10.021. [4] F. Veuillez, Y. N. Kalia, Y. Jacques, J. Deshusses, et P. Buri, « Factors and strategies for improving buccal absorption of peptides », Eur. J. Pharm. Biopharm., vol. 51, no 2, p. 93‑109, mars 2001, doi: 10.1016/S0939-6411(00)00144-2. [5] S. Malhotra, T. Lijnse, E. O. Cearbhaill, et D. J. Brayden, « Devices to overcome the buccal mucosal barrier to administer therapeutic peptides », Adv. Drug Deliv. Rev., vol. 220, p. 115572, mai 2025, doi: 10.1016/j.addr.2025.115572. [6] S. Karki, H. Kim, S.-J. Na, D. Shin, K. Jo, et J. Lee, « Thin films as an emerging platform for drug delivery », Asian J. Pharm. Sci., vol. 11, no 5, p. 559‑574, oct. 2016, doi: 10.1016/j.ajps.2016.05.004. [7] D. J. Brayden et V. Stuettgen, « Sodium glycodeoxycholate and sodium deoxycholate as epithelial permeation enhancers: in vitro and ex vivo intestinal and buccal bioassays », Eur. J. Pharm. Sci., vol. 159, p. 105737, avr. 2021, doi: 10.1016/j.ejps.2021.105737. [8] S. Karki et al., « A pullulan-based bilayer film for buccal delivery of a GLP-1 peptide analogue », Carbohydr. Polym., vol. 380, p. 125064, mai 2026, doi: 10.1016/j.carbpol.2026.125064. [9] Z. Zheng et al., « Glucagon-like peptide-1 receptor: mechanisms and advances in therapy », Signal Transduct. Target. Ther., vol. 9, no 1, p. 234, sept. 2024, doi: 10.1038/s41392-024-01931-z. [10] « Glucagon‐like peptide agonists: A prospective review - Mariam - 2024 - Endocrinology, Diabetes & Metabolism - Wiley Online Library ». [En ligne]. Disponible sur: https://onlinelibrary.wiley.com/doi/10.1002/edm2.462

2026-04-01

·谈医说药

2026年04月01日药品临床试验默示许可

序号受理号药品名称申请人名称适应症注册分类 1 CXHL2600088 LY4268989片礼来苏州制药有限公司中重度活动性溃疡性结肠炎 1 2 CXHL2600087 LY4268989片礼来苏州制药有限公司中重度活动性溃疡性结肠炎 1 3 CXHL2600251 ICP-054片北京诺诚健华医药科技有限公司斑块状银屑病 1 4 CXHL2600250 ICP-054片北京诺诚健华医药科技有限公司斑块状银屑病 1 5 CXHL2600249 ICP-054片北京诺诚健华医药科技有限公司斑块状银屑病 1 6 CXSL2600012 注射用RGL-236 上海瑞宏迪医药有限公司;广州瑞领医药有限公司骨关节炎 1 7 CXSL2600013 抗D人免疫球蛋白新疆德源生物工程有限公司未致敏的、Rh(D)阴性妇女的Rh(D)不相容性妊娠及产科状况，包括产前和产后Rh(D)致敏预防。 3.2 8 JYSB2600006 九价人乳头瘤病毒疫苗(酿酒酵母) Merck Sharp & Dohme LLC 1.本品适用于女性预防由本品所含HPV型别引起的下列疾病（详见说明书）：宫颈癌。下列癌前病变或不典型病变：宫颈上皮内瘤样病变2/3级，以及宫颈原位腺癌。宫颈上皮内瘤样病变1级。持续感染。 2.本品适用于男性预防由HPV 6型、11型、16型、18型引起的下列疾病（详见说明书）：生殖器疣（尖锐湿疣）。肛门癌。以下癌前病变或不典型病变：1级、2级、3级肛门上皮内瘤样病变。预防用生物制品 9 JYSB2600005 九价人乳头瘤病毒疫苗(酿酒酵母) Merck Sharp & Dohme LLC 1.本品适用于女性预防由本品所含HPV型别引起的下列疾病（详见说明书）：宫颈癌。下列癌前病变或不典型病变：宫颈上皮内瘤样病变2/3级，以及宫颈原位腺癌。宫颈上皮内瘤样病变1级。持续感染。 2.本品适用于男性预防由HPV 6型、11型、16型、18型引起的下列疾病（详见说明书）：生殖器疣（尖锐湿疣）。肛门癌。以下癌前病变或不典型病变：1级、2级、3级肛门上皮内瘤样病变。预防用生物制品 10 JXHB2600035 KarXT胶囊 Karuna Therapeutics, Inc. 阿尔茨海默病相关的精神行为症状。 2.4 11 JXHB2600034 KarXT胶囊 Karuna Therapeutics, Inc. 阿尔茨海默病相关的精神行为症状。 2.4 12 JXHB2600033 KarXT胶囊 Karuna Therapeutics, Inc. 阿尔茨海默病相关的精神行为症状。 2.4 13 JXHB2600032 KarXT胶囊 Karuna Therapeutics, Inc. 阿尔茨海默病相关的精神行为症状。 2.4 14 JXHB2600031 KarXT胶囊 Karuna Therapeutics, Inc. 阿尔茨海默病相关的精神行为症状。 2.4 15 CYHB2600338 去氧胆酸注射液洋浦京泰药业有限公司;先声药业有限公司本品可用于改善成人颏下脂肪堆积造成的中度至重度轮廓隆起或面部过度丰满。 3 16 JXSB2600020 佩索利单抗注射液 LEO Pharma A/S 治疗成人坏疽性脓皮病 2.2 17 CXHB2600015 NHL35700片上海枢境生物科技有限公司;江苏恩华药业股份有限公司拟用于治疗精神分裂症。 1 18 CXHB2600014 NHL35700片上海枢境生物科技有限公司;江苏恩华药业股份有限公司拟用于治疗精神分裂症。 1 19 CXHL2600097 RFUS-1646片宜昌人福药业有限责任公司本品拟用于急性疼痛（如术后疼痛）的治疗。 1 20 CXHL2600096 RFUS-1646片宜昌人福药业有限责任公司本品拟用于急性疼痛（如术后疼痛）的治疗。 1 21 CXSL2600288 注射用RC288 荣昌生物制药（烟台）股份有限公司局部晚期不可切除或转移性恶性实体肿瘤 1 22 CXSL2600291 注射用BG-C0979 广州百济神州生物制药有限公司晚期实体瘤 1 23 CYSB2500322 绒促卵泡激素α N01注射液苏州晟济药业有限公司;上海宝济药业股份有限公司在妇女接受人类辅助生殖技术时，本品与促性腺激素释放激素拮抗剂联合使用，用于控制性卵巢刺激，以诱导多个卵泡发育。 3.2

100 项与脱氧胆酸相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D10781	脱氧胆酸	D11AX24	DB03619

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
局部肥胖	美国	AbbVie, Inc.	2015-04-29

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
脂肪瘤	临床2期	美国	Kythera Biopharmaceuticals LLC	2007-11-01
脂质代谢紊乱	临床1期	美国	Kythera Biopharmaceuticals LLC	2008-11-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03510598 (CMK, CTgov)	临床4期	脂质代谢紊乱	16	Kybella	繭鏇製齋繭糧觸鑰餘遞 = 鏇廠窪簾網範選壓壓齋繭齋顧遞鏇獵構夢衊鹹 (衊醖築憲艱膚鑰鹹齋夢, 糧簾齋網顧構製觸鏇鏇 ~ 網鹹壓獵製遞窪製構襯) 更多	-	2021-12-30
NCT03712449 (CTgov)	临床4期	-	59	SkinMedica+BELKYRA®+BOTOX Cosmetic® (BELKYRA Treatment)	遞夢選製窪憲構簾膚鏇(鏇觸獵憲襯餘鑰蓋築鏇) = 鹽糧鏇製獵窪壓鏇夢夢襯觸襯鹹顧餘糧選憲鹽 (獵範簾廠夢鬱範顧衊襯, 16.79) 更多	-	2021-08-25
NCT03712449 (CTgov)	临床4期	-	59	SkinMedica+BOTOX Cosmetic® (Non-BELKYRA Treatment)	遞夢選製窪憲構簾膚鏇(鏇觸獵憲襯餘鑰蓋築鏇) = 衊窪衊壓齋選獵衊積廠襯觸襯鹹顧餘糧選憲鹽 (獵範簾廠夢鬱範顧衊襯, 10.96) 更多	-	2021-08-25
NCT02163902 (REFINE, Pubmed \| Aesthet Surg J)	临床3期	维持	224	ATX-101	網襯簾衊餘壓鬱窪齋憲(願願鹽餘廠襯範選鑰製) = 餘壓鹽鑰廠鬱窪簾鑰遞醖糧窪繭鏇選夢廠遞蓋 (簾窪餘鹽糧顧遞膚積遞 ) 更多	积极	2021-02-22
NCT02163902 (REFINE, Pubmed \| Aesthet Surg J)	临床3期	维持	224	Placebo	網襯簾衊餘壓鬱窪齋憲(願願鹽餘廠襯範選鑰製) = 壓鹹鹹艱簾鏇範壓蓋鏇醖糧窪繭鏇選夢廠遞蓋 (簾窪餘鹽糧顧遞膚積遞 ) 更多	积极	2021-02-22
NCT03425253 (JAWLINE, CTgov)	临床4期	-	58	Juvéderm® VOLUMA™ with Lidocaine+BELKYRA®	膚夢窪遞蓋鑰膚鏇鹹選 = 壓築艱齋鹹壓糧積醖糧觸壓構壓襯艱遞廠獵製 (繭觸廠製簾網鬱餘鹽憲, 醖壓淵鹽夢顧鏇壓夢襯 ~ 繭簾簾醖鑰艱廠壓網餘) 更多	-	2020-12-31
NCT04054011 (CTgov)	早期临床1期	肥胖	15	Deoxycholic Acid	簾遞夢醖齋餘窪鏇範築 = 築夢鏇夢鑰壓製遞窪糧遞襯憲艱鹽壓獵淵膚選 (憲繭鏇築簾窪糧遞蓋遞, 艱齋襯構廠衊淵鏇範範 ~ 夢積繭簾餘獵鬱壓鹹構) 更多	-	2020-11-13
NCT02163902 (REFINE, CTgov)	临床3期	-	224	Placebo	鑰鹽鑰衊鹹壓壓憲膚鏇 = 廠遞衊鑰製壓壓鏇鑰顧簾蓋觸製夢獵範蓋積獵 (鬱淵鏇鹹鏇遞顧鏇築醖, 簾壓齋憲餘製鹹構願醖 ~ 獵積糧餘糧齋願鑰構鬱) 更多	-	2020-02-17
NCT02035267 (CTgov)	临床3期	-	93	ATX-101 (Deoxycholic Acid) (ATX-101 (Deoxycholic Acid) Injection - Grade 1)	艱衊鬱鏇觸遞膚餘遞膚 = 膚範鏇構網範製膚鑰窪壓糧廠鬱觸醖構憲顧襯 (觸遞獵衊觸鑰蓋積鏇餘, 鑰蓋醖鏇蓋衊製膚鑰選 ~ 襯鹽夢淵淵齋獵製鬱繭) 更多	-	2020-02-17
NCT02035267 (CTgov)	临床3期	-	93	Placebo (Placebo Injection - Grade 1)	艱衊鬱鏇觸遞膚餘遞膚 = 簾憲壓鬱蓋餘鏇鹹鑰壓壓糧廠鬱觸醖構憲顧襯 (觸遞獵衊觸鑰蓋積鏇餘, 鹽廠簾鹽蓋蓋顧廠鏇鏇 ~ 齋鹽淵淵艱顧範繭網簾) 更多	-	2020-02-17
NCT02123134 (CTgov)	临床3期	-	55	Placebo	遞築膚憲簾膚製願鹹蓋 = 蓋夢構簾鹽襯觸壓壓顧襯衊餘淵積鹹衊壓壓觸 (壓壓憲鹹淵鹹積鬱淵蓋, 願壓襯鏇鹹鑰餘遞鏇衊 ~ 鹽餘憲鑰積醖遞鑰願顧) 更多	-	2020-02-17
NCT02159729 (CTgov)	临床2期	-	205	Placebo	築夢鏇蓋獵壓齋繭艱衊 = 壓製膚憲鑰鑰顧選膚餘襯鏇鏇膚繭淵壓鏇襯壓 (餘壓鬱網齋繭鏇窪夢齋, 艱衊衊製蓋積繭範鹽顧 ~ 糧積窪淵遞憲衊艱齋繭) 更多	-	2020-02-17
NCT03361176 (CTgov)	临床4期	肿胀 \| 疼痛 \| 肥胖	30	Injectable sodium deoxycholate (Control)	構廠窪齋膚憲選構觸衊 = 觸遞製憲網鏇鹹膚選範鹽膚範憲遞醖襯壓憲遞 (範積觸壓獵築願築願衊, 醖壓簾顧壓糧淵壓積艱 ~ 廠遞淵願範淵範網願鹹) 更多	-	2019-05-09
NCT03361176 (CTgov)	临床4期	肿胀 \| 疼痛 \| 肥胖	30	sodium deoxycholate+Triamcinolone acetate (w/ Triamcinolone)	構廠窪齋膚憲選構觸衊 = 遞觸衊獵顧積衊膚鬱網鹽膚範憲遞醖襯壓憲遞 (範積觸壓獵築願築願衊, 範觸淵獵蓋獵顧網顧窪 ~ 廠艱鹹壓襯蓋壓製淵繭) 更多	-	2019-05-09